RecruitingPhase 2NCT05291676
Systems Investigation of Vaccine Responses in Aging and Frailty
Sponsor
Yale University
Enrollment
96 participants
Start Date
Nov 6, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study will compare the immune response signatures (including immunologic, transcriptomic and metabolomic) of the two influenza vaccines approved for use in adults age 65 and over (Fluad and Fluzone High-Dose).
Eligibility
Min Age: 21 Years
Inclusion Criteria3
- Age 21-40 or 65 and older
- Ability to understand and give informed consent (surrogate consent may apply to nursing home subjects who are decisionally impaired, with verbal assent to be obtained from subject)
- Plan to be in the New Haven, CT area for the next 4-6 weeks
Exclusion Criteria9
- Current use of medication, such as antibiotics in past two weeks. To clarify, patients taking antibiotics for the reason of a current acute infection will not be eligible. Those potential participants receiving antibiotics for prophylaxis purposes will be eligible to participate. The intention is not to create a separate group to drawn conclusions, but not to exclude these participants who are not acutely ill.
- Evidence of acute infection, identified by self- report of fever or symptoms in past two weeks
- Treatment for cancer in past three months.
- Previous adverse reaction to influenza vaccine requiring medical attention, such as allergic response (rash, anaphylaxis) or Guillain-Barré syndrome.
- Pregnant/possibly pregnant.
- History of organ, bone marrow or stem cell transplant, liver cirrhosis, kidney disease requiring dialysis, HIV/AIDS, hepatitis C or active hepatitis B
- Blood donation of 1 pint or more in past 2 months
- Treatment with clinical trial medication
- Presence of any other condition (e.g., geographical or social), actual or projected, that the investigator feels would restrict or limit the patient's participation for the duration of the study. This provision includes participants who have 50% or more missed appointments in the last three months.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALFluzone
Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer
BIOLOGICALFluad
Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05291676
Related Trials
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
NCT013864241 location
Respiratory Virus Sampling and Repository
NCT052662222 locations
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
NCT047948291 location
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
NCT058323072 locations
BPL-1357 Against H1N1 Influenza Virus Challenge
NCT072158582 locations